Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone in the Treatment of Primary Rapid Eye Movement Sleep Behavior Disorder Into Synucleinopathies
NCT04534023Phase 2Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idebenone in rapid eye movement sleep behavior disorder (RBD), sponsored by Ruijin Hospital. Started Aug 2020; status: active, not recruiting.
02
Drugs
idebenone
03
Conditions
rapid eye movement sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT04534023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534023.